TITLE

Personalized Medicine for Cancer in the Developing World

AUTHOR(S)
Smith, Rebecca E.; Pascale, Juan Miguel
PUB. DATE
April 2012
SOURCE
Current Trends in Biotechnology & Pharmacy;Apr2012, Vol. 6 Issue 2, p119
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Personalized Medicine evolved from the genomics era and allows disease prediction based on genetic mutation, and development of individualized health care, both preventive and responsive, as a consequence of a patient's own genetic features. Personalized medicine for cancer is similarly proactive and individualized, based on genetic information and used to manage cancer risk and disease for solid and lymphoproliferative cancers, those with a hereditary basis and those arising spontaneously. In the developing world, cancers now kill more people than infectious disease and while many resource-limited countries still lack basic facilities to care for cancer patients, middleincome countries, such as Panama, are beginning to make simple applications of personalized medicine for cancer diagnosis and treatment. These applications focus on cancers which affect the greatest number of people and those for which proven tests and therapies already exist. Three such cancers are lung, breast and colorectal cancers, which have similarities in the biochemical dysfunctions at their foundations. A limited and affordable portfolio of genetic tests could be established by developing world diagnostic laboratories to aid oncologists in risk assessment, diagnosis, prognosis and pharmaceutical choice in the personalized management of cancer. The establishment and clinical use of these tests in developing world nations will require innovative models of financing and strengthening of human resources and technical and legislative infrastructure.
ACCESSION #
74616655

 

Related Articles

  • Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials Fang, Ping; Hu, Jin-hua; Cheng, Zhi-gang; Liu, Zhe-feng; Wang, Jin-liang; Jiao, Shun-chang // PLoS Clinical Trials;Dec2012, Vol. 7 Issue 12, p1 

    Background: Hepatocellular carcinoma (HCC) is a common cancer associated with a poor prognosis. Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor, a mediator of tumor angiogenesis. Bevacizumab is currently under investigation as treatment for HCC. We performed a...

  • Poor prognosis pushes up complementary spending. Gooding, Lucy // Nursing Standard;2/9/2005, Vol. 19 Issue 22, p8 

    Reports that patients with cancer who have a poor prognosis are most likely to use complementary and alternative therapies. Patients who were reported to most likely use alternative medicine; Head and neck cancer patients are least likely to try alternative medicine; Types of alternative...

  • Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. Tarpgaard, Line S.; Guren, Tormod K.; Glimelius, Bengt; Christensen, Ib J.; Pfeiffer, Per; Kure, Elin H.; Sorbye, Halfdan; Ikdahl, Tone; Yilmaz, Mette; Johansen, Julia S.; Tveit, Kjell Magne // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Background: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab. Patients and...

  • A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Arrieta, Oscar; López-Macías, Diego; Mendoza-García, Víctor-Osvaldo; Bacon-Fonseca, Ludwing; Muñoz-Montaño, Wendy; Macedo-Pérez, Eleazar-Omar; Muñiz-Hernández, Saé; Blake-Cerda, Monika; Corona-Cruz, José-Francisco // Cancer Chemotherapy & Pharmacology;May2014, Vol. 73 Issue 5, p975 

    Purpose: Low-dose, prolonged infusion of gemcitabine has effects similar to standard doses in several cancers. We evaluated the toxicity and efficacy of low-dose gemcitabine in prolonged infusion plus cisplatin in patients with advanced pleural mesothelioma. Methods: Patients with mesothelioma...

  • Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance. Putluri, Nagireddy; Maity, Suman; Kommangani, Ramakrishna; Creighton, Chad J.; Putluri, Vasanta; Fengju Chen; Nanda, Sarmishta; Bhowmik, Salil Kumar; Terunuma, Atsushi; Dorsey, Tiffany; Nardone, Agostina; Xiaoyong Fu; Shaw, Chad; Sarkar, Tapasree Roy; Schiff, Rachel; Lydon, John P.; O'Malley, Bert W.; Ambs, Stefan; Das, Gokul M.; Michailidis, George // Neoplasia;May2014, Vol. 16 Issue 5, p390 

    Breast cancer (BCa) molecular subtypes include luminal A, luminal B, normal-like, HER-2 enriched, and basal-like tumors, among which luminal B and basal-like cancers are highly aggressive. Biochemical pathways associated with patient survival or treatment response in these more aggressive...

  • The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Krenn-Pilko, S; Langsenlehner, U; Thurner, E-M; Stojakovic, T; Pichler, M; Gerger, A; Kapp, K S; Langsenlehner, T // British Journal of Cancer;5/13/2014, Vol. 110 Issue 10, p2524 

    Background:The elevation of the platelet-to-lymphocyte ratio (PLR), an easily applicable blood test based on platelet and lymphocyte counts has been associated with poor prognosis in patients with different types of cancer. The present study was aimed to investigate the prognostic significance...

  • Serum biomarker 3144 m/z for prognostic detection in Chinese postmenopausal breast cancer patients. Yun Gao; ShenHua Xu; Wenming Cao; Zhanhong Chen; Xiaojia Wang; Dehong Zou // Journal of Cancer Research & Therapeutics;2015 Sepcial Issue1, Vol. 11, pC68 

    Context: Breast cancer becomes more prevalent with advancing age. The increased risk of breast cancer needs to be considered when choosing a treatment plan and a kind of detection method for the postmenopausal woman. Better breast cancer prognostication may improve selection of patients for...

  • Zone-size nonuniformity of F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Cheng, Nai-Ming; Fang, Yu-Hua; Lee, Li-yu; Chang, Joseph; Tsan, Din-Li; Ng, Shu-Hang; Wang, Hung-Ming; Liao, Chun-Ta; Yang, Lan-Yan; Hsu, Ching-Han; Yen, Tzu-Chen // European Journal of Nuclear Medicine & Molecular Imaging;Mar2015, Vol. 42 Issue 3, p419 

    Purpose: The question as to whether the regional textural features extracted from PET images predict prognosis in oropharyngeal squamous cell carcinoma (OPSCC) remains open. In this study, we investigated the prognostic impact of regional heterogeneity in patients with T3/T4 OPSCC. Methods: We...

  • Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment. Wu, Huizhe; Guan, Shu; Sun, Mingli; Yu, Zhaojin; Zhao, Lin; He, Miao; Zhao, Haishan; Yao, Weifan; Wang, Enhua; Jin, Feng; Xiao, Qinghuan; Wei, Minjie // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    The calcium-activated chloride channel Ano1 (TMEM16A) is overexpressed in many tumors. Although Ano1 overexpression is found in breast cancer due to 11q13 amplification, it remains unclear whether signaling pathways are involved in Ano1 overexpression during breast cancer tumorigenesis in vivo....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics